Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04323761 |
|
Expanded Access Status :
Approved for marketing
First Posted : March 27, 2020
Last Update Posted : November 13, 2020
|
Sponsor:
Gilead Sciences
Information provided by (Responsible Party):
Gilead Sciences
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Tracking Information | ||||
|---|---|---|---|---|
| First Submitted Date | March 24, 2020 | |||
| First Posted Date | March 27, 2020 | |||
| Last Update Posted Date | November 13, 2020 | |||
| Descriptive Information | ||||
| Brief Title | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | |||
| Brief Summary | The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection. | |||
| Detailed Description | Not Provided | |||
| Study Type | Expanded Access | |||
| Expanded Access Type | Treatment IND/Protocol | |||
| Intervention | Drug: Remdesivir
Intravenous infusion administered over a 30 to 120 minute period
Other Names:
|
|||
| Publications * | Not Provided | |||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
| Recruitment Information | ||||
| Expanded Access Status | Approved for marketing | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Australia, Austria, Belgium, Canada, Cyprus, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Switzerland, United Kingdom, United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT04323761 | |||
| Current Responsible Party | Gilead Sciences | |||
| Original Responsible Party | Same as current | |||
| Current Study Sponsor | Gilead Sciences | |||
| Original Study Sponsor | Same as current | |||
| Collaborators | Not Provided | |||
| Investigators |
|
|||
| PRS Account | Gilead Sciences | |||
| Verification Date | November 2020 | |||